Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Celgene Corporation    CELG

CELGENE CORPORATION

(CELG)
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

CELGENE INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Celgene Corporation - CELG

share with twitter share with LinkedIn share with facebook
share via e-mail
0
02/11/2019 | 05:49pm EDT

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Celgene Corporation (“Celgene”) (NasdaqGS: CELG) to Bristol-Myers Squibb Company (“Bristol-Myers”) (NYSE: BMY). Under the terms of the proposed transaction, shareholders of Celgene will receive only $50.00 in cash and 1.0 shares of Bristol-Myers for each share of Celgene that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company.

If you believe that this transaction undervalues the Company and/or if you would like to discuss your legal rights regarding the proposed sale, you may, without obligation or cost to you, e-mail or call KSF Managing Partner Lewis S. Kahn (lewis.kahn@ksfcounsel.com) toll free at any time at 855-768-1857, or visit https://www.ksfcounsel.com/cases/nasdaqgs-celg/ to learn more.

To learn more about KSF, whose partners include the Former Louisiana Attorney General, visit www.ksfcounsel.com.


© Business Wire 2019
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on CELGENE CORPORATION
10/21BRISTOL MYERS SQUIBB : Announces Extension of the Expiration Date for Exchange O..
AQ
10/16CELGENE : and the Multiple Sclerosis Association of America Take the MS MindShif..
BU
09/24NEWS HIGHLIGHTS : Top Company News of the Day
DJ
09/23CELGENE CORPORATION : Names Second Round of Celgene Cancer Care Links Program Gr..
AQ
09/20CELGENE CORPORATION : Names Second Round of Celgene Cancer Care Links™ Pro..
BU
09/19CELGENE CORPORATION : Report
CO
09/12CELGENE : Announces Phase 3 QUAZAR® AML-001 Study of CC-486 as Maintenance Thera..
BU
09/11Swiss Biotech Anokion Raises $40 Million in Series B Round
DJ
09/09CELGENE : Data from Ozanimod Clinical Development Program in Relapsing Forms of ..
BU
08/29CELGENE : Immatics and Celgene Enter Strategic Collaboration to Develop Novel Ad..
AQ
More news
Financials (USD)
Sales 2019 17 297 M
EBIT 2019 10 044 M
Net income 2019 6 365 M
Debt 2019 1 302 M
Yield 2019 -
P/E ratio 2019 12,5x
P/E ratio 2020 10,4x
EV / Sales2019 4,38x
EV / Sales2020 3,64x
Capitalization 74 411 M
Chart CELGENE CORPORATION
Duration : Period :
Celgene Corporation Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends CELGENE CORPORATION
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 21
Average target price 100,13  $
Last Close Price 104,99  $
Spread / Highest target 14,3%
Spread / Average Target -4,63%
Spread / Lowest Target -19,0%
EPS Revisions
Managers
NameTitle
Mark J. Alles Chairman, President, CEO & COO
David V. Elkins CFO, Principal Accounting Officer & Executive VP
Joseph S. Camardo Senior Vice President-Global Medical Affairs
Jay T. Backstrom Chief Medical Officer
Aijaz Tobaccowalla Chief Digital & Information Officer, Senior VP
Sector and Competitors
1st jan.Capitalization (M$)
CELGENE CORPORATION63.36%74 205
JOHNSON & JOHNSON0.12%340 980
ROCHE HOLDING AG18.71%249 928
MERCK AND COMPANY6.40%208 158
PFIZER-16.54%201 496
NOVARTIS15.69%199 249